TY - JOUR
T1 - European Task Force on Atopic Dermatitis statement on severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection and atopic dermatitis
AU - Wollenberg, Andreas
AU - Flohr, Carsten
AU - Simon, Dagmar
AU - Cork, Michael J.
AU - Thyssen, Jacob P.
AU - Bieber, Thomas
AU - de Bruin-Weller, Marjolein S.
AU - Weidinger, Stephan
AU - Deleuran, Mette
AU - Taieb, Alain
AU - Paul, Carle
AU - Trzeciak, Magdalena
AU - Werfel, Thomas
AU - Seneschal, Julien
AU - Barbarot, Sebastien
AU - Darsow, Ulf
AU - Torrelo, Antonio
AU - Stalder, Jean-Francois
AU - Svensson, Åke
AU - Hijnen, Dirkjan
AU - Gelmetti, Carlo
AU - Szalai, Zsuzsanna
AU - Gieler, Uwe
AU - de Raeve, Linda
AU - Kunz, Barbara
AU - Spuls, Phyllis
AU - von Kobyletzki, Laura B.
AU - Fölster-Holst, Regina
AU - Chernyshov, Pavel V.
AU - Cristen-Zaech, Stéphanie
AU - Heratizadeh, Annice
AU - Ring, Johannes
AU - Vestergaard, Christian
PY - 2020/6/1
Y1 - 2020/6/1
N2 - Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.
AB - Atopic dermatitis (AD) is a complex disease with elevated risk of respiratory comorbidities.1,2 Severely affected patients are often treated with immune-modulating systemic drugs.3,4 On March 11th 2020, the World Health Organization declared the 2019 novel coronavirus severe acute respiratory syndrome (SARS-Cov-2) epidemic to be a pandemic. The number of cases worldwide is increasing exponentially and poses a major health threat, especially for those who are elderly, immuno-compromised, or have comorbidities. This also applies to AD patients on systemic immune-modulating treatment. In these days of uncertainty, reallocation of medical resources, curfew, hoarding, and shutdown of normal social life, patients, caregivers and doctors ask questions regarding the continuation of systemic immune-modulating treatment of AD patients. The ETFAD decided to address some of these questions here.
KW - COVID-19
KW - SARS-CoV-2
KW - atopic dermatitis
KW - immunosuppressant
KW - systemic therapy
UR - http://www.scopus.com/inward/record.url?scp=85083156285&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/jdv.16411
DO - https://doi.org/10.1111/jdv.16411
M3 - Comment/Letter to the editor
C2 - 32223003
SN - 0926-9959
VL - 34
SP - e241-e242
JO - Journal of the European Academy of Dermatology and Venereology
JF - Journal of the European Academy of Dermatology and Venereology
IS - 6
ER -